Interleukin-36 potently stimulates human M2 macrophages, Langerhans cells and keratinocytes to produce pro-inflammatory cytokines

Cytokine

Volumn 84, Issue , 2016, Pages 88-98

  Dietrich, Damien ^a,b   Martin, Praxedis ^a,b   Flacher, Vincent ^c   Sun, Yu ^d   Jarrossay, David ^e   Brembilla, Nicolo ^a,b   Mueller, Christopher ^c   Arnett, Heather A ^d   Palmer, Gaby ^a,b   Towne, Jennifer ^d,f   Gabay, Cem ^a,b  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c INSTITUT DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^d AMGEN INC   (United States)

^e INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Switzerland)

^f JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

IL 1; IL 1R1; IL 36; IL 36R; Myeloid cells; Skin

Indexed keywords

CYTOKINE; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 36; INTERLEUKIN 36 RECEPTOR; INTERLEUKIN 36 RECEPTOR ANTAGONIST; INTERLEUKIN 36BETA; MESSENGER RNA; T6 ANTIGEN; UNCLASSIFIED DRUG; INTERLEUKIN 1 RECEPTOR ACCESSORY PROTEIN; INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN RECEPTOR; INTERLEUKIN-36 RECEPTOR, HUMAN;

ARTICLE; BONE MARROW CELL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; KERATINOCYTE; LANGERHANS CELL; MACROPHAGE; MONOCYTE; MONOCYTE DERIVED DENDRITIC CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SKIN; TONSIL; CELL CULTURE; INFLAMMATION; METABOLISM;

CELLS, CULTURED; DENDRITIC CELLS; HUMANS; INFLAMMATION; INTERLEUKIN-1 RECEPTOR ACCESSORY PROTEIN; KERATINOCYTES; LANGERHANS CELLS; MACROPHAGES; MONOCYTES; MYELOID CELLS; RECEPTORS, INTERLEUKIN; RECEPTORS, INTERLEUKIN-1 TYPE I; RNA, MESSENGER; SKIN;

EID: 84971413794     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2016.05.012     Document Type: Article

References (48)

1. Henry C.M., Sullivan G.P., Clancy D.M., Afonina I.S., Kulms D., Martin S.J. Neutrophil-derived proteases escalate inflammation through activation of IL-36 family cytokines. Cell Rep. 2016, 14:708-722.
2. Towne J.E., Renshaw B.R., Douangpanya J., Lipsky B.P., Shen M., Gabel C.A., et al. Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36alpha, IL-36beta, and IL-36gamma) or antagonist (IL-36Ra) activity. J. Biol. Chem. 2011, 286:42594-42602.
3. Garlanda C., Dinarello C.A., Mantovani A. The interleukin-1 family: back to the future. Immunity 2013, 39:1003-1018.
4. Sims J.E., Smith D.E. The IL-1 family: regulators of immunity. Nat. Rev. Immunol. 2010, 10:89-102.
5. Towne J.E., Garka K.E., Renshaw B.R., Virca G.D., Sims J.E. Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RAcP to activate the pathway leading to NF-kappaB and MAPKs. J. Biol. Chem. 2004, 279:13677-13688.
6. Debets R., Timans J.C., Homey B., Zurawski S., Sana T.R., Lo S., et al. Two novel IL-1 family members, IL-1 delta and IL-1 epsilon, function as an antagonist and agonist of NF-kappa B activation through the orphan IL-1 receptor-related protein 2. J. Immunol. 2001, 167:1440-1446.
7. Sims J.E., March C.J., Cosman D., Widmer M.B., MacDonald H.R., McMahan C.J., et al. cDNA expression cloning of the IL-1 receptor, a member of the immunoglobulin superfamily. Science 1988, 241:585-589.
8. Arend W.P., Joslin F.G., Massoni R.J. Effects of immune complexes on production by human monocytes of interleukin 1 or an interleukin 1 inhibitor. J. Immunol. 1985, 134:3868-3875.
9. Balavoine J.F., de Rochemonteix B., Williamson K., Seckinger P., Cruchaud A., Dayer J.M. Prostaglandin E2 and collagenase production by fibroblasts and synovial cells is regulated by urine-derived human interleukin 1 and inhibitor(s). J. Clin. Invest. 1986, 78:1120-1124.
10. Marrakchi S., Guigue P., Renshaw B.R., Puel A., Pei X.Y., Fraitag S., et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N. Engl. J. Med. 2011, 365:620-628.
11. Onoufriadis A., Simpson M.A., Pink A.E., Di Meglio P., Smith C.H., Pullabhatla V., et al. Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. Am. J. Hum. Genet. 2011, 89:432-437.
12. Farooq M., Nakai H., Fujimoto A., Fujikawa H., Matsuyama A., Kariya N., et al. Mutation analysis of the IL36RN gene in 14 Japanese patients with generalized pustular psoriasis. Hum. Mutat. 2013, 34:176-183.
13. Sugiura K., Takemoto A., Yamaguchi M., Takahashi H., Shoda Y., Mitsuma T., et al. The majority of generalized pustular psoriasis without psoriasis vulgaris is caused by deficiency of interleukin-36 receptor antagonist. J. Invest. Dermatol. 2013, 133:2514-2521.
14. Rossi-Semerano L., Piram M., Chiaverini C., De Ricaud D., Smahi A., Kone-Paut I. First clinical description of an infant with interleukin-36-receptor antagonist deficiency successfully treated with anakinra. Pediatrics 2013, 132:e1043-e1047.
15. Tortola L., Rosenwald E., Abel B., Blumberg H., Schafer M., Coyle A.J., et al. Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk. J. Clin. Invest. 2012, 122:3965-3976.
16. Reddy S., Jia S., Geoffrey R., Lorier R., Suchi M., Broeckel U., et al. An autoinflammatory disease due to homozygous deletion of the IL1RN locus. N. Engl. J. Med. 2009, 360:2438-2444.
17. Aksentijevich I., Masters S.L., Ferguson P.J., Dancey P., Frenkel J., van Royen-Kerkhoff A., et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N. Engl. J. Med. 2009, 360:2426-2437.
18. Palomo J., Dietrich D., Martin P., Palmer G., Gabay C. The interleukin (IL)-1 cytokine family - balance between agonists and antagonists in inflammatory diseases. Cytokine 2015, 76:25-37.
19. Gabay C., Lamacchia C., Palmer G. IL-1 pathways in inflammation and human diseases. Nat. Rev. Rheumatol. 2010, 6:232-241.
20. Gabay C., Towne J.E. Regulation and function of interleukin-36 cytokines in homeostasis and pathological conditions. J. Leukocyte Biol. 2015, 97:645-652.
21. Bachmann M., Scheiermann P., Hardle L., Pfeilschifter J., Muhl H. IL-36gamma/IL-1F9, an innate T-bet target in myeloid cells. J. Biol. Chem. 2012, 287:41684-41696.
22. Nerlich A., Ruangkiattikul N., Laarmann K., Janze N., Dittrich-Breiholz O., Kracht M., et al. C/EBPbeta is a transcriptional key regulator of IL-36alpha in murine macrophages. Biochim. Biophys. Acta 2015, 1849:966-978.
23. Vigne S., Palmer G., Lamacchia C., Martin P., Talabot-Ayer D., Rodriguez E., et al. IL-36R ligands are potent regulators of dendritic and T cells. Blood 2011, 118:5813-5823.
24. Vigne S., Palmer G., Martin P., Lamacchia C., Strebel D., Rodriguez E., et al. IL-36 signaling amplifies Th1 responses by enhancing proliferation and Th1 polarization of naive CD4+ T cells. Blood 2012, 120:3478-3487.
25. Mutamba S., Allison A., Mahida Y., Barrow P., Foster N. Expression of IL-1Rrp2 by human myelomonocytic cells is unique to DCs and facilitates DC maturation by IL-1F8 and IL-1F9. Eur. J. Immunol. 2012, 42:607-617.
26. Foster A.M., Baliwag J., Chen C.S., Guzman A.M., Stoll S.W., Gudjonsson J.E., et al. IL-36 promotes myeloid cell infiltration, activation, and inflammatory activity in skin. J. Immunol. 2014, 192:6053-6061.
27. Frey S., Derer A., Messbacher M.E., Baeten D.L., Bugatti S., Montecucco C., et al. The novel cytokine interleukin-36alpha is expressed in psoriatic and rheumatoid arthritis synovium. Ann. Rheum. Dis. 2013, 72:1569-1574.
28. Magne D., Palmer G., Barton J.L., Mezin F., Talabot-Ayer D., Bas S., et al. The new IL-1 family member IL-1F8 stimulates production of inflammatory mediators by synovial fibroblasts and articular chondrocytes. Arthrit. Res. Ther. 2006, 8:R80.
29. Carrier Y., Ma H.L., Ramon H.E., Napierata L., Small C., O'Toole M., et al. Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis. J. Invest. Dermatol. 2011, 131:2428-2437.
30. Lian L.H., Milora K.A., Manupipatpong K.K., Jensen L.E. The double-stranded RNA analogue polyinosinic-polycytidylic acid induces keratinocyte pyroptosis and release of IL-36gamma. J. Invest. Dermatol. 2012, 132:1346-1353.
31. Segueni N., Vigne S., Palmer G., Bourigault M.L., Olleros M.L., Vesin D., et al. Limited contribution of IL-36 versus IL-1 and TNF pathways in host response to mycobacterial infection. PLoS One 2015, 10:e0126058.
32. Bozoyan L., Dumas A., Patenaude A., Vallieres L. Interleukin-36gamma is expressed by neutrophils and can activate microglia, but has no role in experimental autoimmune encephalomyelitis. J. Neuroinflammation 2015, 12:173.
33. Osugi Y., Vuckovic S., Hart D.N. Myeloid blood CD11c(+) dendritic cells and monocyte-derived dendritic cells differ in their ability to stimulate T lymphocytes. Blood 2002, 100:2858-2866.
34. Johnston A., Xing X., Guzman A.M., Riblett M., Loyd C.M., Ward N.L., et al. IL-1F5, -F6, -F8, and -F9: a novel IL-1 family signaling system that is active in psoriasis and promotes keratinocyte antimicrobial peptide expression. J. Immunol. 2011, 186:2613-2622.
35. Zaba L.C., Fuentes-Duculan J., Steinman R.M., Krueger J.G., Lowes M.A. Normal human dermis contains distinct populations of CD11c+BDCA-1+ dendritic cells and CD163+FXIIIA+ macrophages. J. Clin. Invest. 2007, 117:2517-2525.
36. Angel C.E., George E., Brooks A.E., Ostrovsky L.L., Brown T.L., Dunbar P.R. Cutting edge: CD1a+ antigen-presenting cells in human dermis respond rapidly to CCR7 ligands. J. Immunol. 2006, 176:5730-5734.
37. Nestle F.O., Zheng X.G., Thompson C.B., Turka L.A., Nickoloff B.J. Characterization of dermal dendritic cells obtained from normal human skin reveals phenotypic and functionally distinctive subsets. J. Immunol. 1993, 151:6535-6545.
38. Dietrich D., Gabay C. Inflammation: IL-36 has proinflammatory effects in skin but not in joints. Nat. Rev. Rheumatol. 2014, 10:639-640.
39. Blumberg H., Dinh H., Dean C., Trueblood E.S., Bailey K., Shows D., et al. IL-1RL2 and its ligands contribute to the cytokine network in psoriasis. J. Immunol. 2010, 185:4354-4362.
40. Blumberg H., Dinh H., Trueblood E.S., Pretorius J., Kugler D., Weng N., et al. Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation. J. Exp. Med. 2007, 204:2603-2614.
41. Milora K.A., Fu H., Dubaz O., Jensen L.E. Unprocessed interleukin-36alpha regulates psoriasis-like skin inflammation in cooperation with interleukin-1. J. Invest. Dermatol. 2015, 135:2992-3000.
42. Friedrich M., Tillack C., Wollenberg A., Schauber J., Brand S. IL-36gamma sustains a proinflammatory self-amplifying loop with IL-17C in anti-TNF-induced psoriasiform skin lesions of patients with Crohn's disease. Inflamm. Bowel Dis. 2014, 20:1891-1901.
43. Mylonas K.J., Nair M.G., Prieto-Lafuente L., Paape D., Allen J.E. Alternatively activated macrophages elicited by helminth infection can be reprogrammed to enable microbial killing. J. Immunol. 2009, 182:3084-3094.
44. Duluc D., Corvaisier M., Blanchard S., Catala L., Descamps P., Gamelin E., et al. Interferon-gamma reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-associated macrophages. Int. J. Cancer 2009, 125:367-373.
45. Guiducci C., Vicari A.P., Sangaletti S., Trinchieri G., Colombo M.P. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res. 2005, 65:3437-3446.
46. Porcheray F., Viaud S., Rimaniol A.C., Leone C., Samah B., Dereuddre-Bosquet N., et al. Macrophage activation switching: an asset for the resolution of inflammation. Clin. Exp. Immunol. 2005, 142:481-489.
47. Sica A., Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J. Clin. Invest. 2012, 122:787-795.
48. Lamacchia C., Palmer G., Rodriguez E., Martin P., Vigne S., Seemayer C.A., et al. The severity of experimental arthritis is independent of IL-36 receptor signaling. Arthrit. Res. Ther. 2013, 15:R38.